The successful developmentof an optimized PDE7 PET ligand would provide valuable insights intodisease progression, treatment response, and patient stratificationin conditions such as Alzheimer’s disease, Parkinson’sdisease, multiple sclerosis, and chronic inflammation. Here, PDE7A is linked to early-onset autosomal dominant Alzheimer disease.